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Vaccination against AIDS is hampered by great diversity between human immunodeficiency virus (HIV)
strains. Heterologous B-subtype-based simian-human immunodeficiency virus (SHIV) DNA prime and poxvi-
rus boost vaccine regimens can induce partial, T-cell-mediated, protective immunity in macaques. We analyzed
a set of DNA, recombinant fowlpox viruses (FPV), and vaccinia viruses (VV) expressing subtype AE HIV type
1 (HIV-1) Tat, Rev, and Env proteins and SIV Gag/Pol in 30 pigtail macaques. SIV Gag-specific CD4 and CD8
T-cell responses were induced by sequential DNA/FPV vaccination, although lower FPV doses, VV/FPV vacci-
nation, and DNA vaccines alone were not as consistently immunogenic. The SHIV AE DNA prime, FPV boost
regimens were significantly less immunogenic than comparable B-subtype SHIV vaccination. Peak viral load
was modestly (0.4 log10 copies/ml) lower among the AE subtype SHIV-immunized animals compared to
controls following the virulent B subtype SHIV challenge. Protection from persistent high levels of viremia and
CD4 T-cell depletion was less in AE subtype compared to B subtype SHIV-vaccinated macaques. Gag was
highly immunodominant over the other AE subtype SHIV vaccine proteins after vaccination, and this immu-
nodominance was exacerbated after challenge. Interestingly, the lower level of priming of immune responses
did not blunt postchallenge Gag-specific recall responses, despite more modest protection. These studies
suggest priming of T-cell immunity to prevent AIDS in humans is possible, but differences in the immunoge-
nicity of various subtype vaccines and broad cross-subtype protection are substantial hurdles.
The efficiency of T-cell-mediated clearance of human immu-
nodeficiency virus (HIV)-infected cells by candidate prophy-
lactic vaccines is currently being assessed (22). Vaccine-in-
duced T-cell responses correlate with partial protection from
disease in macaques following various virulent primate lenti-
virus challenge experiments (5). Heterologous prime and boost
HIV vaccine strategies involving priming by DNA vaccination
and boosting with recombinant attenuated poxvirus vectors
(such as fowlpox virus [FPV]) encoding common HIV or sim-
ian immunodeficiency virus (SIV) antigens reliably induce T-
cell immune responses in outbred nonhuman primates. Reduc-
tions in viral levels and retention of CD4 T cells in macaques
challenged with SHIV strains closely related to the vaccine
antigens have been reported (3, 5, 10). Some but not all SIV
vaccination studies using similar heterologous prime/boost vac-
cine modalities have also shown positive results using chal-
lenge strains closely matched to vaccine antigens (17, 27).
Heterologous prime/boost regimens have to date had mixed
success in human studies (3, 16, 17, 21). The ability of T-cell-
based vaccine regimens to protect macaques or humans from
more diverse primate lentivirus strains remains to be defined.
The global HIV type 1 (HIV-1) epidemic consists primarily
of non-B-subtype group M HIV-1 strains. Despite this, the
majority of vaccines evaluated in preclinical and clinical trials
are based on subtype B forms present in developed countries
within Europe, North America, and Australia. The circulating
recombinant subtype AE is common in many Southeast Asian
countries, including Thailand, although no preclinical efficacy
studies or clinical trials with subtype AE vaccines have been
reported. We previously demonstrated the safety and immu-
nogenicity of subtype AE HIV-1 DNA and FPV vaccines in
macaques (12), modeled on our previous macaque and human
work with subtype B HIV-1 and SHIV vaccines (8, 9, 18–20).
In this study we analyzed a set of subtype AE SHIV vaccines
expressing SIV Gag and Pol and HIV-1 subtype AE Env, Tat,
and Rev for immunogenicity and efficacy in pigtail macaques.
A disadvantage of prime/boost vaccination strategies in the
field is the requirement for multiple vaccinations and the rel-
atively poor priming of immune responses with DNA vaccina-
tion alone. Recent studies suggest that dual poxvirus regimens,
such as vaccinia virus (VV) priming and FPV boosting, are
highly immunogenic (4, 23). Since both are live vector vaccines,
a single immunization of each component may suffice. In ad-
dition, it is possible, based on suboptimal results from recent
human studies, that increased doses of DNA and/or FPV vac-
cines could improve immunogenicity and efficacy (13).
In efforts to improve and further understand the limitations
of DNA/poxvirus prime/boost regimens, we studied multigenic
subtype AE SHIV DNA, vaccinia virus, and fowlpox virus
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vaccines for immunogenicity and protective efficacy in 30 pig-
tail macaques. Comparator regimens included DNA vaccina-
tion alone, a higher dose of the FPV booster vaccines, and a
VV/FPV prime/boost regimen. The macaques were subse-
quently mucosally challenged with a heterologous B subtype
SHIV. The macaques were stratified for the presence of the
Mane-A*10 major histocompatibility complex (MHC) allele
(the first such study in pigtail macaques), and CD8 T-cell
immunogenicity in the subset of animals with this allele was
followed using an MHC tetramer.
MATERIALS AND METHODS
Monkeys. Juvenile Macaca nemestrina monkeys were free from HIV-1/SIV/
simian retrovirus infection and anesthetized with ketamine (10 mg/kg of body
weight, intramuscular [i.m.]) prior to procedures. All experiments were per-
formed according to National Institutes of Health guidelines on the care and use
of laboratory animals and were approved by the University of Melbourne and
CSIRO Livestock Industries Animal Experimentation and Ethics committees.
DNA vaccinations. The DNA vaccine, pHIS-SHIV-AE, was based on the
previously described pHIS-HIV-AE. pHIS-SHIV-AE encodes full-length unmu-
tated SIVmac239 Gag and Pol, HIV-193TH253 Tat, Rev, and Vpu, and the 5- and
3-thirds of HIV-193TH253 Env. Genes were inserted into the vector pHIS-64
(Coley Pharmaceutical Group, Wellesley, MA) behind the human cytomegalo-
virus immediate-early promoter. Plasmid vector pHIS-64 has kanamycin resis-
tance, a bovine growth hormone poly(A) termination signal, and 64 CpG motifs
in addition to those naturally present that are primate optimized. Empty vector
plasmid DNA, pHIS, served as a control vaccine. Plasmid pHIS-SHIV-AE for
immunization was prepared by QIAGEN (Hilden, Germany), and control DNA
vaccine pHIS was prepared using the EndoFree plasmid Giga kit (QIAGEN).
Plasmid DNA in normal saline was injected i.m. at 1 mg/ml at weeks 0 and 4
(Table 1).
Recombinant fowlpox virus and vaccinia virus vaccines. Construction of the
FPV and VV vaccines has been described previously (7). A single FPV-
SHIV-AE was constructed, modeled on an FPV-HIV-1-AE vaccine, which ex-
pressed almost all the antigens expressed by the pHIS-SHIV-AE DNA vaccine:
SIV Gag/Pol from the F6,7,9 site, an HIV-193TH253 Tat/Rev fusion product from
the REV site, and HIV-193TH253 Env, mutated to remove the middle third of the
gene. Three separate VV recombinants were constructed encoding either wild-
type SIV gag/pol, an HIV-193TH253 Tat/Rev fusion product, or the mutated
HIV-193TH253 Env (Table 1).
Intracellular IFN- staining (ICS). Induction of antigen-specific intracellular
gamma interferon (IFN-) expression in CD3 CD8 or CD3 CD4 T lym-
phocytes was assessed by flow cytometry as previously described (11, 21). Briefly,
200 l whole blood was incubated with 1 g/ml overlapping 15-mer peptide pools
in dimethyl sulfoxide or dimethyl sulfoxide alone and the costimulatory antibod-
ies anti-CD28 and anti-CD49d (BD Biosciences Pharmingen [BD], San Diego,
CA) for 7 h. Brefeldin A (10 g/ml; Sigma) was included during the last 5 h of
the incubation. Anti-CD3–phycoerythin, anti-CD4–fluorescein isothiocyanate,
and anti-CD8–peridinin chlorophyll a protein antibodies (clones SP34, M-T477,
and SK1, respectively; BD) were added to each well and incubated for 30 min.
Red blood cells were lysed (FACS lysing solution; BD) and washed with phos-
phate-buffered saline, and the remaining cells were permeabilized (FACS per-
meabilizing solution 2; BD). Permeabilized cells were then incubated with anti-
human IFN-–allophycocyanin antibody (clone B27; BD) prior to fixing with
formaldehyde and acquisition (LSRII; BD). Acquisition data were analyzed
using Flowjo version 6.3.2 (Tree Star, Ashland, OR). The percentage of antigen-
specific gated lymphocytes expressing IFN- was assessed in both CD3 CD4
and CD3 CD8 lymphocyte subsets. Peptides used were all 15-mers overlap-
ping by 11 amino acids (aa) and were either obtained from the NIH AIDS
Research and Reference Reagent Program (SIV Gag and Pol) or purchased
from Auspep (HIV-193TH253 Tat, Rev, and Env).
MHC typing and Mane-A*10/KP9 tetramer analyses. Both reference strand-
mediated conformational analysis and sequence-specific primer–PCR were used
to identify Mane-A*10 animals capable of responding to the SIV Gag KP9
epitope as previously described (26). Briefly, the reference strand-mediated
conformation analysis method used an ABI Prism 377 DNA sequencer (Applied
Biosystems, Foster City, Calif.) to heteroduplex a 677-bp fragment of pigtail
macaque MHC class I cDNA product with labeled rhesus macaque alleles
Mamu-A*15, Mamu-A*20, and Mamu-B*60 reference strands. Mane-A*10 het-
eroduplexes were identified by running clones with unique mobility patterns.
Data were analyzed using DAx data acquisition and analysis software (Van
Mierlo Software, Eindhoven, The Netherlands) (26). Mane-A*10-specific prim-
ers were used to confirm the Mane-A*10 status of pigtail macaques by sequence-
specific primer–PCR on peripheral blood mononuclear cell cDNA as previously
described using three separate primer sets (26). KP9-specific T-cell responses
were monitored by flow cytometry using a KP9/Mane-A*10 tetramer as previ-
ously described (1, 26). The Mane-A*10 polypeptide, human 2-microglobulin,
and KP9 peptide (GL Biochem, Shanghai, China) were complexed to form the
KP9/Mane-A*10 tetramer, which was subsequently conjugated with phyco-
erythrin. Fresh whole blood (200 l) was stained with the KP9/Mane-A*10
tetramer (1:200 to 1:400 dilution) and then counterstained with anti-CD3–fluo-
rescein isothiocyanate (clone SP34; Becton-Dickinson) and anti-CD8–allophy-
cocyanin (clone SK1; BD). Acquisition was performed on an LSR II flow cy-
tometer (BD) and analyzed using Flowjo version 6.3.2 (Tree Star).
SHIV challenge of macaques. To assess vaccine efficacy, all macaques were
atraumatically inoculated intrarectally with SHIVmn229 (5  104 50% tissue
culture infective doses [TCID50]/ml) in 0.5-ml doses over 2 days (total, 105
TCID50/ml) as previously described (11). The administered dose of 105 TCID50
represents 500 monkey infectious doses (MID). SHIV viremia was quantified
by reverse transcriptase real-time PCR on an ABI 7700 machine as described
above except a TaqMan probe was used instead of a molecular beacon to detect
fluorescence (11). Depletion of peripheral CD4 T cells was monitored by flow
cytometry as described elsewhere (6).
Power and statistical considerations. The primary end points, set prior to
starting the study, were differences in outcome of SHIV challenge (peak and set
point SHIV viremia and set point peripheral CD4 T-cell levels) between vacci-
nated and control groups. Based on previous studies with this challenge stock
(11), six macaques/group powered the study (80%;   0.05) to detect 0.5 log10
differences in both peak (week 2) and set point (mean of weeks 4 to 11) plasma
TABLE 1. Vaccination and challenge regimens
Vaccine
regimen n Animal nos.
a
Subtype AE SHIV immunization at:
Week 0 Week 4 Week 8 Week 22 (all groups)
Control 6 6167, 6352, 5350,
6264, 5620, 6376
Control pHIS-empty
(1 mg, i.m.)
Control pHIS-empty
(1 mg, i.m.)
Control FPV-M3 (3  108
PFU, i.m.)
Two-DNA/FPV-hi 6 5396, 5616, 6279,
5085, 5912, 5396
DNA pHIS-SHIV-AE
(1 mg, i.m.)
DNA (1 mg) pHIS-SHIV-AE FPV-SHIV-AE (3  108
PFU, i.m.)
Two-DNA/FPV 6 6276, 6370, 5023,
6284, 6263, 6353
DNA pHIS-SHIV-AE
(1 mg, i.m.)
DNA pHIS-SHIV-AE
(1 mg, i.m.)
FPV-SHIV-AE (5  107
PFU, i.m.)
SHIVmn229 (subtype B)
challenge (105
TCID50, intrarectal)
Three-DNA 6 5614, 6351, 5618,
6364, 6173, 6371
DNA pHIS-SHIV-AE
(1 mg, i.m.)
DNA pHIS-SHIV-AE
(1 mg, i.m.)
DNA pHIS-SHIV-AE
(1 mg, i.m.)
VV/FPV 6 6349, 6377, 6259,
6363, 6262, 6388
VV-SIV Gag/Pol, VV-HIV-1AE
Env, VV-HIV-1AE Tat/Rev
(each, 108 PFU, i.m.)
FPV-SHIV-AE (3  108
PFU, i.m.)
a Animal numbers in bold indicate those that expressed the Mane-A*10 allele and were studied with the Mane-A*10/KP9 tetramer.
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SHIV RNA and 5% set point CD4 T lymphocytes between groups. Week 11 was
chosen as the end of the set point time period based on previous studies (11), as
all macaques were likely to be alive and contributing data points up to that time
but at least some control macaques were likely to be euthanized shortly there-
after. Statistical comparisons of immunogenicity and efficacy across vaccine
groups utilized a Kruskal-Wallis analysis of variance (ANOVA) test for overall
significance, with a Dunn’s multiple comparisons test between individual groups.
A nonparametric two-way ANOVA test (on ranks) was used for statistical com-
parisons across vaccine groups of both the T-cell responses to the various pep-
tides and the effectiveness of the SHIV vaccination subtype (AE or B), and a
Bonferroni posttest was used to compare between individual peptides or between
subtypes within each vaccine group. For comparisons between two groups (e.g.,
all vaccinated animals versus controls), we used a Mann-Whitney test.
RESULTS
Vaccine groups. Our previous work with subtype B SHIV-
based DNA prime/FPV boost regimens demonstrated high
levels of T-cell immunogenicity and partial protection from
higher viral loads and CD4 T-cell depletion following a subtype
B SHIV challenge (10). To both assist evaluating the efficacy of
subtype AE regimens suitable for use in Southeast Asia and
assess protection across diverse subtypes, we studied four sep-
arate subtype AE SHIV vaccine regimens in groups of six
macaques (Table 1). We included arms with (i) higher doses on
the FPV boost vaccination (based on earlier work with FPV
doses in macaques (12), (ii) DNA vaccination only (based on
surprisingly good efficacy despite limited immunogenicity with
this arm in the previous subtype-B SHIV trial [9]), and (iii) VV
prime/FPV boost (based on our own and previous reports
demonstrating strong T-cell immunogenicity with this ap-
proach [4, 23]). The vaccine regimens are shown in Table 1.
T-cell responses to Gag postvaccination. The kinetics, mag-
nitude, and phenotype of the cellular response induced by
vaccination were quantified by antigen-specific CD4 and CD8
T-cell expression of IFN- by ICS assays in all 30 macaques at
multiple time points after vaccination (Fig. 1). The high-dose
DNA/FPV vaccine regimen was overall the most immuno-
genic, inducing a mean response to a pool of SIV Gag peptides
in CD8 T cells of 0.51% (range, 0.05 to 1.35%) and in CD4 T
cells of 0.26% (range, 0.07 to 0.46) 1.5 weeks after the final
vaccination (Fig. 1a). The mean SIV Gag-specific CD8 T-cell
responses at weeks 1.5 to 4 postvaccination in the DNA/FPV
high-dose FPV regimen were significantly greater than con-
trols (by Kruskal-Wallis across all groups, ANOVA, P	 0.004;
Dunn’s multiple comparison test, P 	 0.01). The mean SIV
Gag-specific CD4 T-cell responses postvaccination in both the
DNA/FPV high-dose and low-dose regimens were also signif-
icantly greater than controls (Kruskal-Wallis, P  0.001;
Dunn’s multiple comparison test, P 	 0.01).
Compared to the DNA/FPV group with the high dose of
FPV (DNA/FPV-hi), the other vaccination regimens induced
lower mean levels of antigen-specific T cells, although there
was significant variability between the outbred animals and
there were no statistically significant differences between the
other groups of six animals. CD8 T-cell responses 1.5 weeks
after the final vaccination in the DNA/FPV low-dose regimen
were 0.08% (
0.06% standard error [SE]; range, 0.02 to
0.15%), in the VV/FPV regimen they were 0.16% (
0.12%
SE; range, 0.00 to 0.77%), in the DNA-only regimen they were
0.01% (
0.01% SE; range, 0.00 to 0.03%), and in the controls
they were all 0.00%. Utilizing VV instead of DNA as the
priming vaccination prior to the FPV booster did not elevate
responses relative to the DNA/FPV-hi regimen. Three DNA
vaccinations alone without FPV boosting induced much lower
levels of SIV Gag-specific IFN--expressing CD4 and CD8 T
cells that were indistinguishable from controls.
T-cell responses to other antigens postvaccination. All the
DNA, VV, and FPV vaccines expressed HIV-1 subtype AE
FIG. 1. Time course of mean cellular immune responses and stan-
dard error following vaccination. Groups of macaques were immu-
nized with two-DNA/FPV–low-dose FPV (black circles), two-DNA/
FPV–high-dose FPV (black triangles), three-DNA (gray squares), VV/
FPV (gray triangles), or control vaccines (open circles) as shown in
Table 1. (A to D) CD4 and CD8 T-cell responses are shown in the left
and right panels, respectively, in response to stimulation with SIV Gag
15-mer peptide pool (A), SIV Pol 15-mer peptide pool (B), HIV-1
subtype AE Env 15-mer peptide pool (C), or a combined pool of
HIV-1 subtype AE Tat and Rev 15-mer peptide pools (D). (E) CD8
T-cell responses to the SIV Gag epitope KP9 were measured in the
subset of macaques that were Mane-A*10 by MHC tetramer staining.
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Env, Tat, and Rev antigens and SIVmac251 Pol. A set of 15-mer
peptides overlapping by 11 amino acids to the homologous
HIV-193TH253 Env, Tat, and Rev was constructed and used to
assess T-cell immunogenicity to these antigens. Responses to
the overlapping peptides spanning the HIV-1 Env, a combined
pool of HIV-1 Tat/Rev, and polymerase of SIV, were minimal
(Fig. 1a to d), with the CD8 T-cell responses being significantly
lower than those observed for SIV Gag (P 	0.008, nonpara-
metric two-way ANOVA). Peak CD8 or CD4 T-cell responses
after the last vaccination to Pol, Env, and Tat/Rev were only
0.20, 0.13, and 0.23%, respectively, and were not signif-
icantly different from controls.
Responses to immunodominant KP9 epitope postvaccina-
tion. A subset of 11 of the 30 pigtail macaques expressed the
Mane-A*10 MHC class I allele as identified by reference strand
conformational analysis and sequence-specific PCR (data not
shown). The Mane-A*10 molecule presents the dominant SIV
Gag epitope KP9, and we recently developed and validated a
Mane-A*10/KP9 tetramer for use in sensitively detecting KP9-
specific T cells (25, 26). The Mane-A*10 macaques were ran-
domly distributed across the five groups of vaccinated and
control macaques. The CD8 T-cell responses detected by
Mane-A*10/KP9 tetramer staining were higher than those de-
tected by the functional production of IFN- in response to
Gag in the ICS assay, peaking at 2.2% in one animal in the
DNA/FPV-hi regimen 1.5 weeks after the FPV boost. The
mean response across all the prime/boost groups (DNA/FPV
or VV/FPV) was 0.76% 1.5 to 4 weeks after the last vaccina-
tion, compared to a mean response in controls of 0.00% or of
macaques vaccinated with DNA only of 0.11% (P  0.025 by
Kruskal-Wallis; P 	 0.05 by Dunn’s multiple comparison post
test).
SHIV challenge. The HIV-1HXB2-derived SHIVmn229 chal-
lenge stock was inoculated intrarectally (105 TCID50 or 500
MID) into all 30 macaques 14 weeks after the last vaccination.
CD4 T cells and plasma SHIV RNA were followed for 20
weeks, unless macaques were euthanized to avoid AIDS-re-
lated illnesses (Fig. 2 and 3). The six control macaques receiv-
ing DNA and FPV vaccines not expressing SHIV antigens had
high peak levels of SHIV RNA (mean, 7.77 log10 copies/ml;
range, 7.29 to 8.32) following inoculation and at set point
(weeks 4 to 11; mean, 5.6 log10 copies/ml). All six control
macaques lost peripheral CD4 T cells precipitously, declining
to a mean of only 0.6% of total lymphocytes (range, 0.2 to
1.2%) 4 weeks after challenge. Four of the six macaques were
euthanized within 15 weeks of inoculation with incipient AIDS.
Effects of vaccination on viral load postchallenge. All 24
vaccinated macaques became infected, and there was very lim-
ited protection afforded by the SHIV-AE vaccine regimens
from high levels of the subtype B SHIV replication or CD4
T-cell depletion. The mean peak SHIV viral load across all 24
vaccinated macaques was significantly but modestly lower (0.41
log10 copies/ml) than in the control animals (Fig. 2 and 3) (P
0.046, Mann-Whitney). Mean peak viral load in the control
animals was 7.77 log10 copies/ml, compared to 7.39 log10 cop-
ies/ml in the DNA/FPV, 7.36 log10 copies/ml in the DNA/FPV-
hi, 7.26 log10 copies/ml in the DNA only, and 7.43 log10 cop-
ies/ml in the VV/FPV group (overall range, 6.68 to 8.03). Set
point viral load was defined prior to challenge as the mean viral
load over weeks 4 to 11 following challenge, when viral load is
relatively stable and all 30 animals were likely to be still alive.
Set point SHIV viral load was only marginally and not statis-
tically significantly lower than controls in the vaccine groups
vaccinated with the DNA/FPV-hi and DNA/FPV arms (0.47
and 0.24 log10 copies/ml lower, respectively).
Effects of vaccination on CD4 T-cell depletion postchal-
lenge. There was a nonsignificant trend towards retention of
total peripheral CD4 T cells with vaccines compared to con-
FIG. 2. Outcome of SHIVmn229 challenge. Each macaque was chal-
lenged intrarectally with a MID of 500 SHIVmn229 14 weeks post-
final immunization. Blood samples were analyzed for plasma SHIV
RNA by real-time PCR (left panel) and for peripheral CD4 T-cell loss
(right panel). (A) Mean (
 SE of the mean) plasma SHIV RNA and
CD4 T cells for each vaccine group. (B to F) Plasma SHIV RNA and
CD4 T-cell responses for individual macaques grouped for each vac-
cine regimen.
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trols (P  0.074, Mann-Whitney). Although the group immu-
nized with the two-DNA/FPV-hi regimen had higher set point
CD4 T-cell levels between weeks 4 and 11 (mean, 6.05% CD4
T lymphocytes; range, 0.63 to 15.5%) compared to controls
(1.23%; range, 0.15 to 3.71%), there were no significant dif-
ferences between any of the vaccine groups (P  0.3, Kruskal-
Wallis ANOVA). The retention of CD4 T cells in the two-
DNA/FPV-hi group was primarily driven by three animals
(6279, 5085, 5912) (Fig. 2D) which had recovered total CD4 T
cells of 8.3, 12.8, and 17.9%, respectively, by week 11. The
mean set point levels of peripheral CD4 T cells in the two-
DNA/FPV-vaccinated group (2.56%), the three-DNA group
(3.07%), and the VV/FPV group (2.04%) were not signifi-
cantly different from controls (1.23%).
The 30 animals were followed for up to 20 weeks following
SHIV challenge (Fig. 2B to F). Overall, half (15 of 30) of the
animals were euthanized with incipient AIDS between weeks
11 and 20. These included four animals in control group, two
in the DNA/FPV group, three in the DNA/FPV-hi group, two
in the three-DNA group, and four in the VV/FPV group.
Immune responses to Gag following challenge. Gag-specific
CD8 T cells expressing IFN- were dramatically boosted after
challenge in vaccinated macaques (Fig. 4a, right panel). Con-
trol macaques did not mount large Gag-specific CD8 T-cell
responses postchallenge (mean response 3 weeks after chal-
lenge was 0.2%; range, 0.0 to 0.4%). Significantly higher mean
peak Gag-specific CD8 T-cell responses postchallenge were
observed in DNA/FPV-hi- and DNA/FPV-vaccinated animals
over controls (P  0.003, Kruskal-Wallis ANOVA; P 	 0.05,
Dunn’s multiple comparison test) (Fig. 5a). Mean Gag-specific
CD8 T cells peaked 3 weeks following challenge at 12.2%
(range, 2.4 to 20.0%) in the DNA/FPV-hi group. The DNA/
FPV low-dose vaccine group had a similar mean postchallenge
CD8 T-cell response (10.6%; range, 5.4% to 19.8%).
A slow postchallenge increase in IFN--expressing Gag-spe-
cific CD4 T cells was also observed in some vaccinated ma-
caques after SHIV challenge despite depletion of total CD4 T
cells in all animals (Fig. 4a, left panel). Data were not available
from all macaques at time points because of the massive loss of
CD4 T cells in many animals. Data were censored where there
were too few macaques (	3 out of 6 within the group) with
sufficient peripheral CD4 T cells (1%) to estimate the mean
number of SHIV-specific CD4 T cells. Despite these limita-
tions, a proportion of CD4 T cells expressed IFN- in response
to Gag stimulation in the vaccinated animals, reaching a mean
of 2.1% by 11 weeks after SHIV challenge. Anamnestic CD4
and CD8 T-cell responses to Pol, Env, and a combined Tat/Rev
peptide pool were low, sporadic among the vaccine groups, and
not significantly greater than controls.
FIG. 3. Outcome of challenge. All 24 vaccinated animals were com-
pared to the six controls for peak viral load (VL) (A) and set point
CD4 T-cell levels (B) (mean, weeks 4 to 11). P values are for Mann-
Whitney tests. pc, postchallenge.
FIG. 4. Immune responses detected post-SHIVmn229 challenge. (A
to D) Time courses of the mean (
 SE of the mean) CD4 T-cell (left
panel) and CD8 T-cell (right panel) immune responses postchallenge
are shown for each vaccine group by IFN- ICS to stimulation with
SIV Gag 15-mer peptide pool (A), SIV Pol 15-mer peptides (B),
HIV-1 subtype AE Env 15-mer peptide pool (C), or a combined pool
of HIV-1 subtype AE Tat and Rev 15-mer peptide pools (D). (E) CD8
T-cell responses to the SIV Gag epitope KP9 were measured in the
subset of macaques that were Mane-A*10 by MHC tetramer.
(F) Some monkeys mounted responses to other known pigtail ma-
caque Gag epitopes (KW9, CM8, AF9, and GL8) prechallenge, and
these were followed postchallenge by IFN- ICS.
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Responses to immunodominant Gag epitopes postchallenge.
In the subset of animals expressing the Mane-A*10 allele, KP9-
specific CD8 T-cell responses were also analyzed following the
SHIV challenge in Mane-A*10/KP9 tetramer studies (Fig. 4e).
A rise in KP9-specific CD8 T cells from 	0.3% on the day of
challenge to up to 43% of all CD8 T cells within 3 weeks
postchallenge was observed in the vaccinated animals, com-
pared to 	0.7% in controls. All of the vaccinated Mane-A*10
animals had a massive rise in KP9-specific responses, although
peak responses were variable and not significantly different
across the small numbers of Mane-A*10 animals (two to
three/group) within the four vaccine groups.
The KP9 epitope was presented by just over one-third of the
animals, those that expressed Mane-A*10. We previously iden-
tified a number of other strong SIV Gag CD8 T-cell epitopes
presented by pigtail macaques, including KW9 (aa 28 to 36 of
SIVmac239 Gag), CM8 (Gag aa 417 to 424), AF9 (Gag aa 371
to 379), and GL8 (Gag aa 142 to 149) (15). Early after vacci-
nation we screened all 24 vaccinated macaques for responses at
these epitopes by IFN- ICS and identified 6 animals respond-
ing to one or more of these epitopes. We followed these ma-
caques for epitope-specific responses by IFN- ICS after chal-
lenge (Fig. 4f). Overall, the pattern of anamnestic CD8 T-cell
responses to these epitopes was similar to that observed for
total Gag responses by ICS or KP9-specific responses by MHC
tetramer, except that patterns of immunodominance could be
discerned. KW9 was the strongest response studied, with three
of the four responders reaching ICS responses of over 10%. In
animal 6263, which had responses to both KW9 and CM8, the
KW9 response was immunodominant. Similarly, animal 5023
had responses to both the KW9 and GL8 epitopes, and the
KW9 epitope was also immunodominant. Animal 5912 had
responses to three epitopes, AF9, CM8, and GL8, and the AF9
response was the immunodominant response. In a post hoc
analysis, we also studied whether responding to one or more of
these Gag epitopes improved outcome of infection. The six
vaccinated animals that responded to at least one of these
other defined Gag epitopes had significantly lower set point
viral load (P  0.001, nonparametric two-way ANOVA) and
higher set point CD4 T-lymphocyte levels (P  0.012) than
the 18 vaccinated animals not responding to these epitopes
(P  0.001 and 0.012, respectively; nonparametric two-way
ANOVA).
Vaccination enhances Gag immunodominance. The vaccine
regimens resulted in an increase in the mean postvaccination
Gag-specific responses over responses to the other vaccine
antigens (Fig. 5b). After challenge, however, a much greater
mean increase in the Gag responses over the other antigens
was observed in all vaccine groups (Fig. 5c) (P  0.006,
Kruskal-Wallis ANOVA), and there was nearly a 100-fold
mean increase in Gag immunodominance in the DNA/FPV
group that was significantly greater than in the controls (P 	
0.05, Dunn’s multiple comparison test). This suggests that the
Gag-specific responses primed by vaccination were highly im-
munodominant on recall following challenge and that the vac-
cines did not efficiently prime broad responses to the other
vaccine antigens.
Comparison of B subtype and AE subtype vaccination. The
genetic diversity of HIV-1 remains a major obstacle to HIV
vaccination. However, the relative efficacy of SHIV vaccination
with one subtype and protection against another subtype has
not previously been studied. We recently performed and re-
ported a separate B subtype SHIV DNA prime/fowlpox virus
boost vaccine study using the same B subtype SHIVmn229 in-
trarectal challenge stock as used in this AE subtype SHIV
study (9). Two of the vaccine groups in both studies received
identical vaccine regimens (the DNA/FPV low-dose and three-
DNA groups). We therefore compared the immunogenicity
and protective efficacy of these regimens, where the difference
was the subtype of SHIV vaccination (Fig. 6).
There was a lower effectiveness of the AE subtype SHIV
vaccination strategies compared to the B subtype SHIV strat-
egy. The AE subtype DNA/FPV regimen was considerably less
immunogenic than the B subtype SHIV DNA/FPV regimen
for Gag-specific T-cell responses. The mean proportion of
FIG. 5. Immunodominant Gag cytotoxic T-lymphocyte responses
postchallenge (pc). (A) Peak Gag-specific CD8 T-cell responses post-
challenge are shown for each animal in each vaccine group. (B and C)
Gag immunodominance (measured as the ratio of Gag to [Env plus
Pol plus Tat/Rev] specific CD8 T-cell responses) for each animal in
each vaccine group after vaccination (mean, weeks 1.5 to 14 post-final
vaccination) (B) and after challenge (mean, weeks 1 to 11) (C). The P
values for differences between vaccine groups were determined using
Dunn’s multiple comparison posttest to a Kruskal-Wallis ANOVA.
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CD8 T cells responding to Gag at 4 weeks after the last vac-
cination in the B subtype SHIV vaccination was 1.4% (range,
0.4 to 2.6%) compared to 0.2% in the AE SHIV vaccination
(range, 0 to 0.6%) (P  0.009, Mann-Whitney) (Fig. 6a). Both
the AE and B subtype DNA vaccination-only regimens were
equally poorly immunogenic (mean responses postvaccination
of 	0.1%) at inducing detectable responses by IFN- ICS.
The B subtype vaccination also produced a superior out-
come following the B subtype SHIV challenge compared to the
AE subtype SHIV vaccination (Fig. 6b and c). There were
lower set point plasma SHIV RNA levels in both the subtype
B DNA/FPV and DNA vaccination regimens (4.86 log10 cop-
ies/ml) compared to the corresponding AE subtype regimens
(5.53 log10 copies/ml, respectively; P  0.005, nonparametric
two-way ANOVA). The control of viremia by the subtype B
regimens resulted in a trend towards greater retention of set
point CD4 T cells in the subtype B DNA/FPV and DNA
vaccination regimens (12.8%) compared to the corresponding
AE subtype regimens (2.8%; P  0.064, nonparametric two-
way ANOVA).
We were also interested in comparing the anamnestic CD8
T-cell response to Gag after challenge. Given the poorer im-
munogenicity after vaccinations and outcome of challenge, we
assumed that the recall response to infection would be poorer.
We were surprised to find that Gag-specific CD8 T-cell re-
sponses after challenge were nearly identical in the subtype B
and AE regimens with DNA/FPV and DNA-only vaccine reg-
imens (Fig. 6d).
DISCUSSION
Containment of HIV-1 replication by prophylactic vaccina-
tion is a major global scientific and public health challenge.
The great diversity of HIV-1 strains and difficulty in inducing
broad neutralizing antibodies makes this an even more formi-
dable challenge. Subtype-specific HIV-1 vaccines expressing a
broad array of HIV-1 antigens may be required for maximal
effectiveness. Inducing protective immunity to various non-B
subtypes of HIV-1 present in less developed countries is, how-
ever, poorly studied.
We previously performed a macaque study showing that
subtype AE HIV-1 DNA and FPV vaccines expressing Gag,
Pol, Env, Tat, and Rev were safe and induced significant CD4
and CD8 T-cell responses to subtype AE overlapping peptide
sets spanning Gag, Pol, Env and, to a lesser extent, Tat and
Rev (12). To further determine the preclinical efficacy of sim-
ilar subtype AE vaccines in a heterologous challenge system,
we constructed subtype AE SHIV DNA, FPV, and VV vac-
cines expressing SIV Gag and Pol and HIV-1 AE subtype Env,
Tat, and Rev and evaluated their efficacy against a subtype B
SHIV, heterologous for the HIV-1 genes. The DNA and FPV
vaccines expressed all genes within a single construct. Gag-
specific CD4 and CD8 T-cell responses were induced by vac-
cination, but minimal Pol, Env, Tat, or Rev responses were
detected. Further, the levels of Gag-specific CD8 T-cell re-
sponses induced by the AE subtype SHIV were less than those
observed in previous studies of subtype B SHIV vaccination.
The reasons for the poorer immunogenicity were not clear.
Although the B and AE subtype DNA vaccines were very
similarly constructed, the subtype B SHIV FPV vaccines ex-
pressed either SIV Gag or Pol or HIV-1 Env from separate
FPV recombinants. There were modestly reduced levels of
Gag expression from the AE subtype SHIV FPV compared to
the B subtype SHIV B FPV in vitro (8). It is possible that the
reduced expression of Gag or other genes in the AE subtype
FPV SHIV recombinant expressing all five SHIV genes com-
promised immunogenicity, although the similar pure HIV-1
FPV recombinant constructed in an identical manner was
FIG. 6. Comparison of the immunogenicity and efficacy of subtype
B (black circles) and subtype AE (gray squares) SHIV vaccination of
groups of six pigtail macaques. Two vaccine regimens, DNA/FPV–low-
dose FPV (left panel) and DNA only (right panel), were identical
between the B and AE subtype SHIV vaccinations, and both were
challenged intrarectally with the same dose, route, and stock of
SHIVmn229. (A) Vaccine-induced SIV Gag-specific CD8 T-cell re-
sponses by IFN- ICS. (B) Plasma SHIV RNA by real-time PCR after
challenge. (C) Peripheral CD4 T cells after challenge. (D) Postchal-
lenge SIV Gag-specific CD8 T-cell responses by IFN- ICS.
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broadly immunogenic in macaques (12). Further, the VV vac-
cines used in the VV/FPV group did express the SHIV genes
from separate recombinants and were still only moderately
immunogenic. This study illustrates the potential unforeseen
difficulties in translating results from HIV-1 to SHIV multi-
genic vector vaccines and vice versa.
The poorer immunogenicity of the subtype AE vaccines was
also followed by poorer efficacy after the subtype B SHIV
challenge compared to a homologous B subtype challenge.
There was a modest reduction in peak viral load but no signif-
icant differences in set point viral load or CD4 T-cell count.
The group of six macaques with the best immunogenicity
(DNA/FPV-hi) had two animals (5912 and 5085) controlling
viral load to below the limits of quantitation by week 20, which
resulted in preservation of total CD4 T cells of 10%; these
were the only animals to do so (Fig. 2D). Interestingly, animal
5912 was also the only animal that recognized three previously
defined strong Gag CD8 T-cell epitopes (AF9, GL8, and
CM9), suggesting anecdotally that broad recognition of CD8
T-cell epitopes may be helpful in controlling viremia (Fig. 4f).
Although we were not able to consistently induce broad re-
sponses to other SHIV proteins by these vaccines, our results
lend support to the concept that this should be advantageous
(2). It would ultimately also be insightful to immunize ma-
caques against a B subtype SHIV and then challenge with a
subtype AE SHIV; however, such virus constructs are not
available at present.
Given the poor virologic outcome, there was a remarkably
robust anamnestic Gag CD8 T-cell response postchallenge.
For example, by KP9 MHC tetramer studies the vaccinated
Mane-A*10 animals had a mean KP9-specific CD8 T-cell
response postchallenge of 26% of all CD8 T cells by 2.5 weeks
after challenge, compared to 	0.3% in the controls. This is
similar to that observed in vaccinated Mamu-A*01 rhesus
macaques studied for CM9-specific responses by MHC tet-
ramer after SHIV challenge (3, 5, 24). Indeed, the anamnestic
Gag-specific CD8 T-cell response by IFN- ICS in the subtype
AE SHIV DNA/FPV- or DNA-vaccinated animals was virtu-
ally identical to that in the subtype B SHIV DNA/FPV- or
DNA-vaccinated animals (Fig. 6d), even though these animals
had a much better virologic and immunologic outcome for
challenge with the same SHIV virus.
There are several potential explanations for this intriguing
observation of postchallenge immunogenicity. First, the quality
of the CD8 or CD4 T-cell immunity induced by the subtype B
and AE SHIV vaccinations may have been different even
though the magnitude of the anamnestic response to the chal-
lenge virus was the same. For example, the greater levels of
responses induced by vaccination may have primed T-cell re-
sponses with higher avidity, affinity, or the ability to secrete
multiple cytokines/chemokines that were more effective at
clearing virus-infected cells at the same total levels of re-
sponses (14). Second, the B subtype SHIV vaccination may
have primed a broader response than the subtype AE SHIV
vaccination, as discussed above. Third, partial earlier control of
the B subtype SHIV challenge virus resulting in less-profound
CD4 T-cell depletion may have facilitated a broader recogni-
tion of nonvaccine SHIV antigens, although we previously
showed this was not related to early neutralizing antibody
responses (9). The subtype AE SHIV-vaccinated animals were
remarkable for their very poor recognition of non-Gag anti-
gens (Fig. 3b to d and 5b and c), suggesting the strong domi-
nance of the primed Gag-specific responses to the detriment of
a broader array of responses. The breadth of the response is
likely to be crucial when faced with a heterologous challenge.
In conclusion, this large macaque study of subtype AE SHIV
vaccines found that although Gag-specific CD8 and CD4 T-cell
responses were primed by vaccination, the responses induced
were narrow and insufficient to result in consistent control of a
heterologous B subtype SHIV challenge. Further refinements
in vaccine design or delivery to induce broader cross-subtype
T-cell responses to non-B subtype HIV antigens will likely be
required to facilitate more effective control of HIV replication
in less-developed countries.
ACKNOWLEDGMENTS
This work was supported by the NIH HIV Vaccine Design and
Development Team award N01-AI-05395, Australian National Health
and Medical Research Council grants 299907, 251653, 350841,
and 251654, a James S. McDonnell Foundation Award, a Sylvia and
Charles Viertel fellowship, and the Australian Centre for HIV and
Hepatitis Research.
We thank all members of the Australian Thai HIV Vaccine Con-
sortium. We thank Sheilajen Alcantara, Jeanette Reece, Erin Taylor,
Liyen Loh, Rachel Amos-Ritchie, Mary Ann Anderson, Rhonda
Voysey, Jie Lin, and Andrew Brooks for expert technical assistance
and Kim Szalnowski, Andrew Sydenham, and Leah Protyniak for ex-
pert animal care.
REFERENCES
1. Altman, J. D., P. Moss, P. Goulder, D. H. Barouch, W. M. McHeyzer, J. I.
Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of anti-
gen-specific T lymphocytes. Science 274:94–96.
2. Amara, R. R., J. M. Smith, S. I. Staprans, D. C. Montefiori, F. Villinger, J. D.
Altman, S. P. O’Neil, N. L. Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G.
Herndon, J. M. McNicholl, H. M. McClure, B. Moss, and H. L. Robinson.
2002. Critical role for Env as well as Gag-Pol in control of a simian-human
immunodeficiency virus 89.6P challenge by a DNA prime/recombinant mod-
ified vaccinia virus Ankara vaccine. J. Virol. 76:6138–6146.
3. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. O’Neil, S. Staprans,
D. Montefiori, Y. Xu, J. Herndon, L. Wyatt, M. Candido, N. Kozyr, P. Earl,
J. Smith, H. Ma, B. Grimm, M. Hulsey, J. Miller, H. McClure, J. McNicholl,
B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and
prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:
69–74.
4. Anderson, R. J., C. M. Hannan, S. C. Gilbert, S. M. Laidlaw, E. G. Sheu, S.
Korten, R. Sinden, G. A. Butcher, M. A. Skinner, and A. V. Hill. 2004.
Enhanced CD8 T cell immune responses and protection elicited against
Plasmodium berghei malaria by prime boost immunization regimens using a
novel attenuated fowlpox virus. J. Immunol. 172:3094–3100.
5. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W.
Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A.
Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S.
Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S.
Gelman, D. C. Montefiori, and M. G. Lewis. 2000. Control of viremia and
prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA
vaccination. Science 290:486–492.
6. Batten, C. J., R. D. Rose, K. M. Wilson, M. B. Agy, S. Chea, I. Stratov, D. C.
Montefiori, and S. J. Kent. 2006. Comparative evaluation of simian, simian-
human, and human immunodeficiency virus infections in the pigtail macaque
(Macaca nemestrina) model. AIDS Res. Hum. Retrovir. 22:580–588.
7. Boyle, D. B., M. Anderson, R. Amos, R. Voysey, and B. E. H. Coupar. 2004.
Construction of recombinant fowlpox viruses carrying multiple vaccine an-
tigens and immunomodulatory molecules. BioTechniques 37:104–111.
8. Coupar, B. E., D. F. Purcell, S. A. Thomson, I. A. Ramshaw, S. J. Kent, and
D. B. Boyle. 2006. Fowlpox virus vaccines for HIV and SHIV clinical and
pre-clinical trials. Vaccine 24:1378–1388.
9. Dale, C. J., R. De Rose, I. Stratov, S. Chea, D. Montefiori, S. A. Thomson,
I. A. Ramshaw, B. E. Coupar, D. B. Boyle, M. Law, and S. J. Kent. 2004.
Efficacy of DNA and fowlpox virus prime/boost vaccines for simian/human
immunodeficiency virus. J. Virol. 78:13819–13828.
10. Dale, C. J., R. De Rose, K. Wilson, H. Croom, S. A. Thomson, B. E. Coupar,
A. J. Ramsay, D. F. Purcell, R. Ffrench, M. Law, S. Emery, D. A. Cooper, I. A.
Ramshaw, D. B. Boyle, and S. J. Kent. 2004. Evaluation in macaques of
VOL. 81, 2007 AE DNA AND FOWLPOX VIRUS PRIME/BOOST VACCINES 299
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vac-
cines co-expressing IFN- or IL-12. Vaccine 23:188–197.
11. Dale, C. J., X. S. Liu, R. De Rose, D. F. Purcell, J. Anderson, Y. Xu, G. R.
Leggatt, I. H. Frazer, and S. J. Kent. 2002. Chimeric human papilloma
virus-simian/human immunodeficiency virus virus-like-particle vaccines: im-
munogenicity and protective efficacy in macaques. Virology 301:176–187.
12. De Rose, R., S. Chea, C. J. Dale, J. Reece, C. S. Fernandez, K. M. Wilson, S.
Thomson, I. A. Ramshaw, B. E. Coupar, D. B. Boyle, M. T. Sullivan, and S. J.
Kent. 2005. Subtype AE HIV-1 DNA and recombinant fowlpox virus vac-
cines encoding five shared HIV-1 genes: safety and T cell immunogenicity in
macaques. Vaccine 23:1949–1956.
13. De Rose, R., M. T. Sullivan, C. J. Dale, A. Kelleher, S. Emery, C. D. A., I. A.
Ramshaw, D. Boyle, and S. J. Kent. 2006. Dose-response relationship of
DNA and recombinant fowlpox virus prime-boost vaccines: implications for
future trials. Hum. Vaccines 2:134–136.
14. Estcourt, M. J., A. J. Ramsay, A. Brooks, S. A. Thomson, C. J. Medveckzy,
and I. A. Ramshaw. 2002. Prime-boost immunization generates a high fre-
quency, high-avidity CD8 cytotoxic T lymphocyte population. Int. Immu-
nol. 14:31–37.
15. Fernandez, C. S., I. Stratov, R. De Rose, K. Walsh, C. J. Dale, M. Z. Smith,
M. B. Agy, S. L. Hu, K. Krebs, D. I. Watkins, H. O’Connor, D., M. P.
Davenport, and S. J. Kent. 2005. Rapid viral escape at an immunodominant
simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope ex-
acts a dramatic fitness cost. J. Virol. 79:5721–5731.
16. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Becker, S. C.
Gilbert, A. V. Hill, G. L. Smith, and A. McMichael. 1998. Enhancement of
MHC class I-restricted peptide-specific T cell induction by a DNA prime/
MVA boost vaccination regime. Vaccine 16:439–445.
17. Horton, H., T. U. Vogel, D. K. Carter, K. Vielhuber, D. H. Fuller, T. Shipley,
J. T. Fuller, K. J. Kunstman, G. Sutter, D. C. Montefiori, V. Erfle, R. C.
Desrosiers, N. Wilson, L. J. Picker, S. M. Wolinsky, C. Wang, D. B. Allison,
and D. I. Watkins. 2002. Immunization of rhesus macaques with a DNA
prime/modified vaccinia virus Ankara boost regimen induces broad simian
immunodeficiency virus (SIV)-specific T-cell responses and reduces initial
viral replication but does not prevent disease progression following challenge
with pathogenic SIVmac239. J. Virol. 76:7187–7202.
18. Kelleher, A. D., R. L. Puls, M. Bebbington, D. Boyle, R. Ffrench, S. J. Kent,
S. Kippax, D. F. Purcell, S. Thomson, H. Wand, D. A. Cooper, and S. Emery.
2006. A randomized, placebo-controlled phase I trial of DNA prime, recom-
binant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20:294–
297.
19. Kent, S. J., C. J. Dale, C. Ranasinghe, I. Stratov, R. De Rose, S. Chea, D.
Montefiori, S. Thomson, I. A. Ramshaw, B. E. Coupar, D. B. Boyle, M. Law,
K. M. Wilson, and A. J. Ramsay. 2005. Mucosally-administered human-
simian immunodeficiency virus DNA and fowlpox virus-based recombinant
vaccines reduce acute phase viral replication in macaques following vaginal
challenge with CCR5-tropic SHIVSF162P3. Vaccine 23:5009–5021.
20. Kent, S. J., A. Zhao, S. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw.
1998. Enhanced T cell immunogenicity and protective efficacy from a HIV-1
vaccine regimen consisting of consecutive priming with DNA and boosting
with recombinant fowlpox virus. J. Virol. 72:10180–10188.
21. Maecker, H. T., H. S. Dunn, M. A. Suni, E. Khatamzas, C. J. Pitcher, T.
Bunde, N. Persaud, W. Trigona, T. M. Fu, E. Sinclair, B. M. Bredt, J. M.
McCune, V. C. Maino, F. Kern, and L. J. Picker. 2001. Use of overlapping
peptide mixtures as antigens for cytokine flow cytometry. J Immunol. Meth-
ods 255:27–40.
22. Nabel, G. J. 2001. Challenges and opportunities for development of an AIDS
vaccine. Nature 410:1002–1007.
23. Ranasinghe, C., J. C. Medveczky, D. Woltring, K. Gao, S. Thomson, B. E.
Coupar, D. B. Boyle, A. J. Ramsay, and I. A. Ramshaw. 2006. Evaluation of
fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal
and systemic immunity against HIV-1. Vaccine 24:5881–5895.
24. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans,
Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris,
R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V.
Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins,
G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm,
J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A.
Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori,
A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L.
Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002.
Replication-incompetent adenoviral vaccine vector elicits effective anti-immu-
nodeficiency-virus immunity. Nature 415:331–335.
25. Smith, M. Z., C. J. Dale, R. De Rose, I. Stratov, C. S. Fernandez, A. G.
Brooks, J. T. Weinfurter, K. Krebs, C. Riek, D. I. Watkins, D. H. O’Connor,
and S. J. Kent. 2005. Analysis of pigtail macaque major histocompatibility
complex class I molecules presenting immunodominant simian immunode-
ficiency virus epitopes. J. Virol. 79:684–695.
26. Smith, M. Z., C. S. Fernandez, A. Chung, C. J. Dale, R. De Rose, J. Lin, A. G.
Brooks, K. C. Krebs, D. I. Watkins, D. H. O’Connor, M. P. Davenport, and
S. J. Kent. 2005. The pigtail macaque MHC class I allele Mane-A*10 pre-
sents an immunodominant SIV Gag epitope: identification, tetramer devel-
opment and implications of immune escape and reversion. J. Med. Primatol.
34:282–293.
27. Wilson, N. A., J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott,
E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, T. Soma, M. R.
Reynolds, E. Rakasz, R. Rudersdorf, A. B. McDermott, H. O’Connor, D.,
T. C. Friedrich, D. B. Allison, A. Patki, L. J. Picker, D. R. Burton, J. Lin, L.
Huang, D. Patel, G. Heindecker, J. Fan, M. Citron, M. Horton, F. Wang, X.
Liang, J. W. Shiver, D. R. Casimiro, and D. I. Watkins. 2006. Vaccine-
induced cellular immune responses reduce plasma viral concentrations after
repeated low-dose challenge with pathogenic simian immunodeficiency virus
SIVmac239. J. Virol. 80:5875–5885.
300 DE ROSE ET AL. J. VIROL.
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
